Intellia Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Intellia Therapeutics est John Leonard, nommé en Jan2018, a un mandat de 6.83 ans. La rémunération annuelle totale est $ 11.66M, composée du salaire de 5.7% et des bonus 94.3%, y compris les actions et options de la société. détient directement 0.82% des actions de la société, d'une valeur de $ 12.63M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.2 ans et 9.6 ans.

Informations clés

John Leonard

Directeur général

US$11.7m

Rémunération totale

Pourcentage du salaire du PDG	5.7%
Durée du mandat du directeur général	6.8yrs
Propriété du PDG	0.8%
Durée moyenne d'occupation des postes de direction	6.2yrs
Durée moyenne du mandat des membres du conseil d'administration	9.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de John Leonard a-t-elle évolué par rapport aux bénéfices de Intellia Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$522m
Jun 30 2024	n/a	n/a	-US$509m
Mar 31 2024	n/a	n/a	-US$486m
Dec 31 2023	US$12m	US$660k	-US$481m
Sep 30 2023	n/a	n/a	-US$462m
Jun 30 2023	n/a	n/a	-US$453m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$10m	US$630k	-US$474m
Sep 30 2022	n/a	n/a	-US$442m
Jun 30 2022	n/a	n/a	-US$400m
Mar 31 2022	n/a	n/a	-US$369m
Dec 31 2021	US$10m	US$600k	-US$268m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$185m
Mar 31 2021	n/a	n/a	-US$149m
Dec 31 2020	US$4m	US$580k	-US$134m
Sep 30 2020	n/a	n/a	-US$120m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$109m
Dec 31 2019	US$904k	US$559k	-US$100m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$89m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$10m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$83m
Mar 31 2018	n/a	n/a	-US$76m
Dec 31 2017	US$3m	US$396k	-US$68m

Rémunération vs marché: La rémunération totale de John ($USD 11.66M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 2.28M ).

Rémunération et revenus: La rémunération de John a augmenté alors que l'entreprise n'est pas rentable.

PDG

John Leonard (67 yo)

6.8yrs

Titularisation

US$11,657,262

Compensation

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
John Leonard	President	6.8yrs	US$11.66m	0.82% $ 12.6m
Laura Sepp-Lorenzino	Executive VP & Chief Scientific Officer	5.5yrs	US$4.19m	0.019% $ 294.5k
James Basta	Executive VP	3.4yrs	US$3.99m	0.017% $ 269.9k
David Lebwohl	Executive VP & Chief Medical Officer	4.6yrs	US$4.26m	0.029% $ 445.8k
Nessan Bermingham	Founder & Member of Scientific Advisor Board	10.5yrs	US$11.27m	pas de données
Rachel Haurwitz	Co-Founder	10.5yrs	US$311.57k	pas de données
Andrew May	Founder and Member of Scientific Advisor Board	no data	pas de données	pas de données
Jennifer Doudna	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Derrick Rossi	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données

6.2yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 0JBU est chevronnée et expérimentée (6.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
John Leonard	President	10.3yrs	US$11.66m	0.82% $ 12.6m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	no data	US$11.27m	pas de données
Andrew May	Founder and Member of Scientific Advisor Board	no data	pas de données	pas de données
Jennifer Doudna	Founder & Member of Scientific Advisor Board	9.6yrs	pas de données	pas de données
Derrick Rossi	Founder & Member of Scientific Advisor Board	9.6yrs	pas de données	pas de données
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	pas de données	pas de données
Arthur Krieg	Member of Scientific Advisory Board	no data	pas de données	pas de données
Beverly Davidson	Member of Scientific Advisory Board	9.8yrs	pas de données	pas de données
Franciscus A. G. Verwiel	Independent Chairman of the Board	7.3yrs	US$499.94k	0.010% $ 155.4k
William Chase	Independent Director	1.6yrs	US$996.21k	0.0067% $ 103.5k

9.6yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0JBU sont considérés comme expérimentés (ancienneté moyenne 9.6 ans).

Intellia Therapeutics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Recent updates

Intellia Therapeutics, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Now 25% overvalued

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations